Getting the Shingrix vaccine after the age of 50 can reduce your chances of developing the painful skin condition known as ...

Shingrix will now challenge Merck & Co.'s Zostavax, and is looking to displace it as the shingles vaccine of choice in the US and beyond. However it must first gain recommendation from a key US ...

Shingles vaccine industry is projected to witness a CAGR of 10.1% during the period 2025-2034. This growth can be attributed ...

Two doses of Shingrix, however, was around 73% effective after the third year. Previously, Zostavax (the live zoster vaccine) was offered to older and immunocompromised adults to prevent shingles ...

A study published in Nature Medicine suggests that people administered Shingrix have a lower risk of dementia compared to those given Zostavax - an older shingles shot based on a different ...